Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06428019 2025-11-05

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 3 Recruiting

170 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05896163 2025-10-20

MAPtivate-6

24 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 2 Completed

20 enrolled

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03198650 2025-10-09

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

35 enrolled

Part1: Advanced B-cell Malignancies

NCT05326308 2025-09-23

ARIADNE

Recruiting

705 enrolled

Phase 3 Active not recruiting

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02475681 2025-08-27

ElevateTN

535 enrolled 19 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03039114 2025-08-21

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

26 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence

NCT06351527 2025-06-19

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Phase 1 Recruiting

78 enrolled

Mature B-cell Malignancies

NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

203 enrolled 43 charts

B-cell Malignancies

NCT04464798 2025-04-29

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

62 enrolled

Lymphoma, Recurrence

NCT03492125 2025-04-10

A Study Of The Selective PKC-β Inhibitor MS- 553

Phase 1/2 Terminated

60 enrolled 20 charts

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04880863 2025-03-03

NT-NAP-102-1

Phase 2 Completed

38 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04277637 2025-02-17

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

437 enrolled

Mature B-Cell Malignancies

NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

111 enrolled

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03836261 2024-12-27

AMPLIFY

984 enrolled 1 FDA

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02612311 2024-12-13

UNITY-CLL

Phase 3 Terminated

603 enrolled 17 charts

BreastDermatologicGenitourinaryHead & NeckThoracic

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04787042 2024-11-15

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Phase 1/2 Recruiting

316 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02569476 2024-10-26

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

119 enrolled 34 charts

Leukemia, Lymphoma

NCT05219513 2024-08-23

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

53 enrolled

Lymphoma, Non-Hodgkin

NCT03866239 2024-08-09

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

47 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Phase 3 Completed

120 enrolled 14 charts

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04434196 2024-07-25

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

16 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04313608 2024-03-25

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

23 enrolled 17 charts

Lymphoma, B-Cell

NCT04657302 2024-01-19

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

30 enrolled